GBA1 and Parkinson disease: Among 65,509 individuals with Parkinson's disease, we identified 9,019 (13.8%) potentially trial-eligible genetic variant carriers, including 6,789 <i>GBA1</i> , 2,084 <i>LRRK2</i> , and 146 dual <i>GBA1-LRRK2</i> carriers.